All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Abbvie Inc.'s agreement to take over Allergan plc in a cash and stock deal worth about $63 billion jarred Wall Street and set pundits mulling the price tag – seen by some as too low – along with the prospects for a satisfying marriage as pipelines are sorted out.